MDS Clinical Trials

15 studies are recruiting for mds in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

   Background: - GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells from a matching donor (r…

   Stage

   Phase 2

   Ages

   6 to 70

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01861106 on ClinicalTrials.gov

2. Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

   This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   13 in total

   Run by

   Stelexis BioSciences

   See if you can join NCT06533761 on ClinicalTrials.gov

3. Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

   The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

   Stage

   Not phased

   Ages

   60 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT03680677 on ClinicalTrials.gov

4. A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

   This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   26 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT07702578 on ClinicalTrials.gov

5. A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

   This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with A…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   21 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT05473910 on ClinicalTrials.gov

6. Familial Investigations of Childhood Cancer Predisposition

   NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT03050268 on ClinicalTrials.gov

7. MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

   This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

   Stage

   Phase 2

   Ages

   2 to 75

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT07493538 on ClinicalTrials.gov

8. BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

   This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT04187105 on ClinicalTrials.gov

9. Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

   This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Diego, San Diego, California

   Locations

   2 in total

   Run by

   Weizmann Institute of Science

   See if you can join NCT07081087 on ClinicalTrials.gov

10. Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

    This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

    Stage

    Phase 2

    Ages

    Up to 21

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04644016 on ClinicalTrials.gov

11. CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

    The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective …

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06326463 on ClinicalTrials.gov

12. A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

    The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome. The main questions it aims to answer are: * Does the combination drug exhibit h…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Montefiore Einstein Medical Center, The Bronx, New York

    Run by

    Treebough Therapies

    See if you can join NCT07006025 on ClinicalTrials.gov

13. Safety of MT-401-OTS in Patients With Relapsed AML or MDS

    This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or </= 10% blast following prior induction therapy …

    Stage

    Phase 1

    Ages

    65 and older

    Site

    City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

    Locations

    3 in total

    Run by

    Marker Therapeutics, Inc.

    See if you can join NCT06552416 on ClinicalTrials.gov

14. A Long Term Follow-up Study of TScan TCR-T Products

    The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and effic…

    Stage

    Not phased

    Ages

    18 to 110

    Site

    City of Hope, Duarte, California

    Locations

    2 in total

    Run by

    TScan Therapeutics, Inc.

    See if you can join NCT06976736 on ClinicalTrials.gov

15. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

    Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

    Stage

    Phase 1

    Ages

    1 to 21

    Site

    Children's Hospital Los Angeles, Los Angeles, California

    Locations

    31 in total

    Run by

    Therapeutic Advances in Childhood Leukemia Consortium

    See if you can join NCT05476770 on ClinicalTrials.gov